Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 222Neoplasms 193Prostatic Neoplasms 158Multiple Myeloma 138Neoplasm Metastasis 115Melanoma 110Colorectal Neoplasms 107Leukemia, Myeloid, Acute 103Lymphoma 97Lung Neoplasms 94Ovarian Neoplasms 84Squamous Cell Carcinoma of Head and Neck 75Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 70Pancreatic Neoplasms 64Triple Negative Breast Neoplasms 62Myelodysplastic Syndromes 62Parkinson Disease 4, Autosomal Dominant Lewy Body 59Hematologic Neoplasms 59Head and Neck Neoplasms 59Recurrence 56Glioblastoma 55Leukemia 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Sarcoma 49Brain Neoplasms 49Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Hepatocellular 47Lymphoma, Follicular 45

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Philadelphia Chromosome × 1 year × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡